Market Size of Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry
Study Period | 2018 - 2029 |
Market Size (2024) | USD 11.59 Billion |
Market Size (2029) | USD 13.30 Billion |
CAGR (2024 - 2029) | 2.78 % |
Fastest Growing Market | Latin America |
Largest Market | Asia-Pacific |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis
The Dipeptide Peptidase 4 Inhibitors Market size is estimated at USD 11.59 billion in 2024, and is expected to reach USD 13.30 billion by 2029, growing at a CAGR of 2.78% during the forecast period (2024-2029).
The COVID-19 pandemic positively impacted the Dipeptide Peptidase 4 (DPP-4) Inhibitors Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. In the current crisis, type 2 diabetes patients are at much higher risk.
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes. DPP4 inhibitors increase insulin and GLP-1 secretion and are commonly prescribed for people suffering from type 2 diabetes. The use of DPP4 inhibitors in patients with COVID-19 with or even without type 2 diabetes offers a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection.
According to International Diabetes Federation (IDF), the adult diabetes population is approximately 537 million currently, and this number is going to increase by 643 million in 2030. Technological advancements have increased over the period leading to several modifications either in the DPP-4 Inhibitor drugs or the formulations being developed.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Segmentation
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a pharmacological class of drugs for treating Type 2 diabetes. They help to control glycemia by increasing the levels of active incretins. The Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is segmented into drugs and geography. The report offers the value (in USD) and volume (in units) for the above segments.
Drugs | |
Januvia (Sitagliptin) | |
Onglyza (Saxagliptin) | |
Tradjenta (Linagliptin) | |
Vipidia (Alogliptin) | |
Galvus (Vildagliptin) | |
Others |
Geography | |||||||||||||
| |||||||||||||
| |||||||||||||
| |||||||||||||
| |||||||||||||
|
Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size Summary
The Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is poised for growth over the forecast period, driven by the increasing prevalence of type 2 diabetes and the rising demand for effective glucose-lowering medications. DPP-4 inhibitors play a crucial role in managing blood sugar levels by enhancing insulin and GLP-1 secretion, making them a popular choice for diabetes treatment. The market's expansion is further supported by technological advancements leading to drug modifications and new formulations. The COVID-19 pandemic has also positively impacted the market, as individuals with diabetes are at higher risk of severe COVID-19 complications, thereby increasing the demand for DPP-4 inhibitors. The market is characterized by a mix of global and regional players, with significant competition and the presence of generic drug manufacturers, particularly in regions like China.
The market landscape is fragmented, with major pharmaceutical companies such as AstraZeneca, Merck, Boehringer Ingelheim, Novartis, and others actively participating. These companies are focusing on expanding their presence in key markets while navigating challenges such as slow economic growth and increased competition. The introduction of cost-effective drug combinations and pricing regulations in countries like India further highlights the dynamic nature of the market. As the adult diabetes population continues to grow, the demand for DPP-4 inhibitors is expected to rise, supported by their role as a complementary therapy to metformin and other diabetes medications. This growth trajectory is anticipated despite the challenges posed by market maturity and regulatory environments in various regions.
Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Drugs
-
2.1.1 Januvia (Sitagliptin)
-
2.1.2 Onglyza (Saxagliptin)
-
2.1.3 Tradjenta (Linagliptin)
-
2.1.4 Vipidia (Alogliptin)
-
2.1.5 Galvus (Vildagliptin)
-
2.1.6 Others
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
2.2.1.3 Rest of North America
-
-
2.2.2 Europe
-
2.2.2.1 France
-
2.2.2.2 Germany
-
2.2.2.3 Italy
-
2.2.2.4 Spain
-
2.2.2.5 United Kingdom
-
2.2.2.6 Russia
-
2.2.2.7 Rest of Europe
-
-
2.2.3 Latin America
-
2.2.3.1 Mexico
-
2.2.3.2 Brazil
-
2.2.3.3 Rest of Latin America
-
-
2.2.4 Asia-Pacific
-
2.2.4.1 Japan
-
2.2.4.2 South Korea
-
2.2.4.3 China
-
2.2.4.4 India
-
2.2.4.5 Australia
-
2.2.4.6 Vietnam
-
2.2.4.7 Malaysia
-
2.2.4.8 Indonesia
-
2.2.4.9 Philippines
-
2.2.4.10 Thailand
-
2.2.4.11 Rest of Asia-Pacific
-
-
2.2.5 Middle East and Africa
-
2.2.5.1 Saudi Arabia
-
2.2.5.2 Iran
-
2.2.5.3 Egypt
-
2.2.5.4 Oman
-
2.2.5.5 South Africa
-
2.2.5.6 Rest of Middle East and Africa
-
-
-
Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size FAQs
How big is the Dipeptide Peptidase 4 Inhibitors Market?
The Dipeptide Peptidase 4 Inhibitors Market size is expected to reach USD 11.59 billion in 2024 and grow at a CAGR of 2.78% to reach USD 13.30 billion by 2029.
What is the current Dipeptide Peptidase 4 Inhibitors Market size?
In 2024, the Dipeptide Peptidase 4 Inhibitors Market size is expected to reach USD 11.59 billion.